Skip to main content

Upstream Bio, Inc.

corporate_fare Company Profile

Upstream Bio, Inc.

UPB·NASDAQ·Life Sciences·CIK 0002022626

Upstream Bio, Inc. is a clinical-stage biotechnology company that develops treatments for inflammatory diseases, primarily focusing on severe respiratory disorders. The company is developing verekitug, a monoclonal antibody that is the only known antagonist in clinical development targeting the receptor for Thymic Stromal Lymphopoietin (TSLP). TSLP is a cytokine that drives inflammatory responses. Verekitug has demonstrated potent inhibition of the TSLP receptor in preclinical and clinical data. Upstream Bio has advanced verekitug into separate Phase 2 trials for severe asthma, including a long-term safety and efficacy extension study (Phase 2 LTE), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company reported positive top-line results in its CRSwNP Phase 2 trial in September 2025 and positive top-line results in its severe asthma Phase 2 trial in February 2026. The Phase 2 COPD trial was initiated in July 2025. Upstream Bio plans to initiate dosing in Phase 3 trials for both severe asthma and CRSwNP in the first quarter of 2027, with a strategy focused on maximizing efficacy without biomarker restriction, and quarterly at-home administration. In 2023, total estimated biologics sales for asthma in the United States, Europe, and Japan markets were approximately $7.5 billion. There are seven biologics approved for severe asthma, four of which are also approved for CRSwNP, and two are also approved for COPD. In December 2021, tezepelumab (Tezspire), a monoclonal antibody targeting the TSLP ligand, was approved by the U.S.

Upstream Bio, Inc. (NASDAQ:UPB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for UPB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-01, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for UPB spans 8-K, 10-Q, 424B5, 10-K.

Recent high-impact activity:

  • Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
  • Upstream Bio Finalizes Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
  • Upstream Bio Reports Q2 2026: $261M Cash, Phase 3 Starts in Q1 2027
  • Upstream Bio Q2 2026: $261M Cash, Phase 3 Trials on Track for Q1 2027, COPD Enrollment Complete
  • Upstream Bio's Verekitug Shows Clinically Meaningful Improvements in 79% of Patients in New Phase 2 CRSwNP Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.85M
Net Income
-$143.44M
Diluted EPS
-$2.66
Op. Cash Flow
-$133.28M
Free Cash Flow
-$133.44M
Operating Income
-$160.36M
Cash & Equivalents
$101.58M
Debt / Equity
0.00×
Net Margin
-50.26×
Shares Outstanding
54.24M sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126188

Short Interest & Short Volume

2.70 days to cover

FINRA reported short interest of 3,550,200 shares in UPB as of the October 30, 2026 settlement, a 20.8% decrease from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 60.1% of UPB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,550,200 shares as of October 30, 2026
Change vs prior period▼ 20.8%
Days to cover2.70 at avg daily volume of 1,316,186
Daily short volume (FINRA facilities)60.1% of 582,463 shares on November 20, 2026
5-day average short volume38.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with U →
$1.62 +1.89% today
52-week range · as of 2026-09-01 $1.62 – $33.68
Market cap
$87.15M
Volume
1.4M (1.1× avg)
3-mo avg 1.3M
Live data · 2026-11-22 09:14 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed UPB - Latest Insights

UPB
Sep 01, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.70
Real-time Price: $1.62 info
Change: -$5.08 (-76%) info
Market Cap: $87.15M info
UPB
Sep 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.70
Real-time Price: $1.62 info
Change: -$5.08 (-76%) info
Market Cap: $87.15M info
UPB
Aug 11, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.26
Real-time Price: $1.62 info
Change: -$5.64 (-78%) info
Market Cap: $87.15M info
UPB
Aug 11, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.26
Real-time Price: $1.62 info
Change: -$5.64 (-78%) info
Market Cap: $87.15M info
UPB
Jun 14, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.36
Real-time Price: $1.62 info
Change: -$4.74 (-75%) info
Market Cap: $87.15M info
UPB
May 18, 2026, 11:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.51
Real-time Price: $1.62 info
Change: -$6.89 (-81%) info
Market Cap: $87.15M info
UPB
May 13, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.04
Real-time Price: $1.62 info
Change: -$7.42 (-82%) info
Market Cap: $87.15M info
UPB
May 13, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.04
Real-time Price: $1.62 info
Change: -$7.42 (-82%) info
Market Cap: $87.15M info
UPB
Mar 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.70
Real-time Price: $1.62 info
Change: -$8.08 (-83%) info
Market Cap: $87.15M info
UPB
Mar 26, 2026, 5:05 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.70
Real-time Price: $1.62 info
Change: -$8.08 (-83%) info
Market Cap: $87.15M info
UPB
Mar 26, 2026, 4:04 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $9.79
Real-time Price: $1.62 info
Change: -$8.17 (-83%) info
Market Cap: $87.15M info
UPB
Mar 26, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $1.62 info
Change: -$7.86 (-83%) info
Market Cap: $87.15M info
UPB
Mar 26, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.48
Real-time Price: $1.62 info
Change: -$7.86 (-83%) info
Market Cap: $87.15M info
UPB
Mar 01, 2026, 9:47 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $7.69
Real-time Price: $1.62 info
Change: -$6.07 (-79%) info
Market Cap: $87.15M info
UPB
Feb 11, 2026, 9:17 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.99
Real-time Price: $1.62 info
Change: -$18.37 (-92%) info
Market Cap: $87.15M info
UPB
Feb 11, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.88
Real-time Price: $1.62 info
Change: -$18.26 (-92%) info
Market Cap: $87.15M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets